Bispecific Antibody

About This Classification

A bispecific antibody is a drug that has been designed to simultaneously target two different antigens. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells. This approach gives additional options in targeted immunotherapy and may help the immune system find and kill the cancer cells.

Myeloma Treatments

GBR 1342

GBR 1342 is a humanized, bispecific monoclonal antibody (bsAb) that is designed to activate the patient's immune system by redirecting immune cells towards tumor tissue, which may lead to targeted destruction of tumors.

Learn more about this treatment


BFCR4350A

BFCR4350A is a bispecific T-cell engager (BiTE) antibody. It targets both the the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and as well as the CD3 antigen found on T lymphocytes.

Learn more about this treatment


JNJ-64007957

JNJ-64007957 is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells.

Learn more about this treatment


AMG 701

AMG 701 is a bispecific antibody that targets both CD-3 and BCMA that is being tested in multiple myeloma.

Learn more about this treatment


AMG 420

AMG 420 is made using Amgen’s proprietary BiTE or “bispecific T-cell engager” technology. AMG 420 consists of two proteins fused together, each designed to interact with a specific target — in this case, BCMA and CD3, a protein found on the surface of T-cells.

Learn more about this treatment


AMG 424

AMG 424 is a novel, humanized, bispecific T cell-recruiting anti-CD3/CD38 antibody.

Learn more about this treatment


CC-93269

CC-93269 is a T-cell bi-specific antibody targeting both BCMA and CD3 in patients with multiple myeloma.

Learn more about this treatment


JNJ-64407564

JNJ-64407564 is a bispecific monoclonal antibody binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells.

Learn more about this treatment


PF-06863135

PF-06863135 is a B-cell Maturation Antigen (Bcma)-cd3 bispecific antibody being tested in multiple myeloma.

Learn more about this treatment

Create Your Account

Create your account today and get matched to myeloma treatments and trials around the US.

  • Find treatments with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new treatments become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account


Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;